Middle-aged people with no memory problems will be prescribed an Alzheimer’s drug in a trial aiming to prevent dementia.
The first participants in Europe will be screened in Britain from Monday, with more than 15 UK centres expected to take part in the global study.
Previous research on patients with Alzheimer’s suggested the treatment could clear toxic brain plaques after just three monthly infusions.
Now scientists will test whether giving the drug, called trontinemab, before symptoms appear can stop Alzheimer’s developing in the first place.
If it proves successful it has the potential to transform how the disease is treated.
